Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

Inclusion Criteria: * Personally submitted written voluntary informed consent to participate in the study * Patients with a diagnosis of parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy. * Corrected serum calcium level is \> 11.3 mg/dL at screening. Exclusion Criteria: * Patients receiving cinacalcet hydrochloride within 2 weeks before screening * Patients diagnosed with hypercalcemia associated with malignant tumors other than parathyroid carcinoma. * Severe heart disease * Severe hepatic dysfunction * Uncontrolled hypertension and/or diabetes * Treatment with an investigational product (drug or medical device) in a clinical study or any study equivalent to clinical study within 12 weeks before screening